The contribution of this pathway to osteosarcoma stemness was further substantiated in our subsequent study, in which we demonstrated that Wnt/β-catenin inhibition with the tankyrase inhibitor IWR-1 reversed the doxorubicin-induced Wnt-activation and acquisition of stemness features, such as expression of pluripotency-related and drug efflux-related markers, in differentiated osteosarcoma cells [177]. This evidence concerns the gene TNKS and osteosarcoma.